Skip to content
naulon

Not checkedNot checked for notices yet.

Increased mortality risk in multiple-myeloma patients with subsequent malignancies: a population-based study in the Netherlands

Mirian Brink, Monique C. Minnema, Otto Visser and 12 more

Blood Cancer Journal · 2022

doi:10.1038/s41408-022-00640-6 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

The rapidly evolving treatment landscape of multiple myeloma (MM) has dramatically improved the survival of MM patients over time. However, there is also a concurrrent increase in the incidence of subsequent primary malignancies (SPMs) [ 1 , 2 , 3 ]. Risk factors associated with SPMs in MM encompass treatment with alkylating agents or immunomodulatory drugs (IMiDs) [ 1 , 4 , 5 , 6 ], environmental exposures, genetic susceptibility to cancer, or combinations of these risk factors [ 7 , 8 ]. As MM survivorship is expected to increase, it is vital for clinicians to know how these risk factors influence SPM development in MM patients. Therefore, this nationwide, population-based study aimed to complement and extend the data on SPMs among MM patients in the Netherlands, assessing prior malignancy diagnoses (PMDs) as a potential proxy for genetic susceptibility to cancer, as well as treatment-related factors. Besides, we assessed whether SPM development was associated with higher mortality risk.

Abstract licence: CC BY-NC-ND

References15

    15 more references, whose wording the paper’s licence keeps private.

    Reads

    Read by people on this page

    None yet.

    Checked or read by AI through naulon

    None yet.

    A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

    Are you an author?

    Is this your paper?

    Claim it to add your note and be paid when agents cite it. Free.